The stock of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) is a huge mover today! About 480,826 shares traded hands or 27.26% up from the average. Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) has declined 17.88% since April 27, 2016 and is downtrending. It has underperformed by 23.11% the S&P500.
The move comes after 7 months negative chart setup for the $160.88 million company. It was reported on Nov, 30 by Barchart.com. We have $3.97 PT which if reached, will make NASDAQ:TTPH worth $8.04M less.
Analysts await Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) to report earnings on February, 28. They expect $-0.58 EPS, down 16.00% or $0.08 from last year’s $-0.5 per share. After $-0.58 actual EPS reported by Tetraphase Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) Ratings Coverage
Out of 11 analysts covering Tetraphase Pharmaceuticals (NASDAQ:TTPH), 1 rate it a “Buy”, 0 “Sell”, while 10 “Hold”. This means 9% are positive. Tetraphase Pharmaceuticals has been the topic of 15 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The rating was downgraded by JMP Securities on Wednesday, September 9 to “Market Perform”. The stock of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) has “Buy” rating given on Thursday, August 6 by Stifel Nicolaus. The firm has “Neutral” rating given on Friday, May 13 by Gabelli. Brean Capital maintained it with “Buy” rating and $51 target price in Thursday, August 6 report. The stock has “Market Perform” rating given by BMO Capital Markets on Tuesday, April 12. The stock has “Buy” rating given by Needham on Thursday, August 6. On Wednesday, September 9 the stock rating was downgraded by Needham to “Hold”. On Thursday, November 19 the stock rating was upgraded by SunTrust to “Buy”. The firm has “Hold” rating by Brean Capital given on Wednesday, September 9. The rating was downgraded by SunTrust on Wednesday, September 9 to “Neutral”.
According to Zacks Investment Research, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts.”
Insitutional Activity: The institutional sentiment increased to 1.12 in Q2 2016. Its up 0.26, from 0.86 in 2016Q1. The ratio increased, as 18 funds sold all Tetraphase Pharmaceuticals Inc shares owned while 26 reduced positions. 14 funds bought stakes while 24 increased positions. They now own 21.31 million shares or 7.27% less from 22.99 million shares in 2016Q1.
Armistice Cap Limited Liability Corporation has 0.79% invested in the company for 482,073 shares. Invesco has 30,843 shares for 0% of their US portfolio. Wellington Ltd Liability Partnership, a Massachusetts-based fund reported 2.47 million shares. Barclays Public Limited Liability Corp has invested 0% of its portfolio in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH). Vanguard Gp accumulated 0% or 1.29 million shares. Northern Corp has 0% invested in the company for 607,567 shares. Clearline Limited Partnership accumulated 377,132 shares or 0.32% of the stock. California Public Employees Retirement Systems holds 0% of its portfolio in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) for 252,400 shares. Legal And General Group Public Ltd Limited Liability Company accumulated 0% or 6,756 shares. Rhenman Partners Asset holds 0.23% or 300,000 shares in its portfolio. Tiaa Cref Invest Mgmt Limited has 0% invested in the company for 230,758 shares. Moreover, Bank & Trust Of Mellon Corporation has 0% invested in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) for 171,552 shares. Dafna Capital Ltd Liability Corporation owns 103,690 shares or 0.35% of their US portfolio. Jpmorgan Chase & accumulated 2,078 shares or 0% of the stock. Acadian Asset Limited Liability Company holds 59,986 shares or 0% of its portfolio.
More notable recent Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) news were published by: Marketwatch.com which released: “Tetraphase’s stock tumbles 21% to record low” on April 15, 2013, also Fool.com with their article: “Why Tetraphase Pharmaceuticals Dropped 74% of Its Value in 2015” published on January 11, 2016, Fool.com published: “Why Tetraphase Pharmaceuticals Inc Stock Was Annihilated Today” on September 09, 2015. More interesting news about Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) were released by: Globenewswire.com and their article: “Tetraphase Pharmaceuticals Reports Second Quarter 2016 Financial Results and …” published on August 04, 2016 as well as Quotes.Wsj.com‘s news article titled: “News Tetraphase Pharmaceuticals Inc.TTPH” with publication date: March 22, 2013.
TTPH Company Profile
Tetraphase Pharmaceuticals, Inc. (Tetraphase), incorporated on July 7, 2006, is a clinical-stage biopharmaceutical company. The Firm uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Firm is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant Gram-negative infections. The Firm also develops TP-6076 for multidrug-resistant Gram- negative infections.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.